悉尼科技大学的安•辛普森教授是该研究的领头人,她说道,“获得Melligen细胞的专利,我们整个团队都特别高兴。”
'This takes us a step closer to releasing diabetics from the need to inject insulin daily, and more importantly, protecting them from the debilitating complications of the disease, such as blindness, kidney failure and cardiovascular problems.'
“糖尿病患者要是能不用天天注射胰岛素就好了,而Melligen细胞让我们离这样的未来又近了一步,更重要的是,它还能保护患者,使其不因产生并发症而日渐虚弱,如失明、肾衰竭及心血管疾病。”
The researchers are now working with US clinical biotech firm PharmaCyte Biotech to develop the research into new treatments.
研究人员目前正与美国临床生物科技公司PharmaCyte Biotech合作,将该项研究开发成新型疗法。
PharmaCyte specialises in the development of targeted treatments for cancer and diabetes using its signature live cell encapsulation technology.
PharmaCyte公司运用其招牌技术——活细胞胶囊技术,专门研发癌症及糖尿病的靶向疗法。
This technology, known as Cell-in-a-Box, is a key process in the commercialisation of the Melligen cell as a revolutionary treatment.
该技术被称为Cell-in-a-Box,是Melligen细胞成为突破性疗法、实现商业化的一大关键。
【澳洲新基因改良技术:不打胰岛素也能治糖尿病】相关文章:
★ 灭霸同款水果意外走红!果农:我不知道灭霸是谁,但我很感谢他!
★ “大白兔冰淇淋”在美火爆,奶糖原料被抢光,冠生园:没授权啊
★ 再见北上广!2019年大学生就业报告发布,毕业生正流向二线城市
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15